- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
NPPA panel fixes the retail price of uncoated sustained-release tablets containing Medroxyprogesterone Acetate, details
New Delhi: The National Pharmaceutical Pricing Authority (NPPA) panel has fixed the retail price of uncoated sustained release tablet containing Medroxyprogesterone Acetate IP 30 mg, manufactured by Synokem Pharmaceuticals and marketed by Serum Institute of India Limited.
In addition to this, the NPPA has fixed the retail price of uncoated sustained release tablet containing Medroxyprogesterone Acetate IP 30 mg manufactured by Synokem Pharmaceuticals and marketed by Torrent Pharmaceuticals.
The retail price of each uncoated sustained-release tablet containing Medroxyprogesterone Acetate IP 30 mg has been set at Rs 14.04 per tablet excluding GST.
Medroxyprogesterone is a progestin (a form of progesterone), a female hormone, that helps regulate ovulation and menstrual periods. Ovulation is the process of the release of an egg from an ovary.
Medroxyprogesterone is used to treat conditions such as irregular or absent menstrual periods, or abnormal uterine bleeding. It is also used to decrease the risk of endometrial hyperplasia (a condition that may lead to uterine cancer) while taking estrogens.
Medroxyprogesterone is also used as part of combination hormone replacement therapy with estrogens to reduce menopause symptoms (such as hot flashes). Medroxyprogesterone is added to estrogen replacement therapy to reduce the risk of cancer of the uterus.
This drug is not recommended during pregnancy as it causes birth defects. The drug is also not recommended during breastfeeding as it passes through breast milk.
Medroxyprogesterone acetate inhibits gonadotropin production, reduces nuclear estrogen receptors and DNA synthesis in epithelial cells of the endometrium, and induces p53 dependant apoptosis in cancer cell lines. These oral tablets have a half-life of 40-60 hours.
Medroxyprogesterone acetate inhibits the production of gonadotropin, thus preventing follicular maturation and ovulation, which is responsible for its ability to prevent pregnancy. This action also thins the endometrium.
This recommendation came during the 40th meeting of the Multidisciplinary Committee of Experts, held on March 14, 2022, under the convenorship of Shri Manmohan Sachdeva, Advisor(cost), through video-conferencing.
After detailed deliberation, the Committee recommended the retail price of each uncoated sustained release tablet containing Medroxyprogesterone Acetate IP 30 mg, for Synokem Pharmaceuticals Limited (manufacturer) and Serum Institute of India Limited ( marketer) at Rs 14.04 per tablet excluding GST as detailed below.
Computation of Retail Price per Tablet | Source/Tablet | Amount |
Derived retail price of Medroxyprogesterone acetate sustained-release tablets 30mg | Note 1 | Rs.14.04 per tablet excluding GST |
Company Claimed Price excluded GST(per tablet) | Rs.16.52 | |
Recommended price excluding GST(per tablet) | Rs.14.04 |
Note 1
Derived retail price as per recommended of pronabsen committee:
P(s)=P*[1+a{(s-s*)/s*}]
Where :P(s)=Price ceiling of strengths
P*=pricing ceiling for reference strengths
S=strength in terms of API content
s*=reference strength
a=0.8for tablets/capsule and 0.7 for injections
Similarly, the Committee deliberated upon the matter in detail and recommended the retail price of each uncoated sustained release tablet contains Medroxyprogesterone Acetate IP 30 mg for Synokem Pharmaceuticals (manufacturer) and Torrent Pharmaceuticals (marketer) at Rs. 14.04 per tablet excluding GST as detailed below:
Computation of Retail Price per Tablet | Source/ Method | /- mount (Rs.) |
Derived retail price of Medroxyprogesterone Acetate Sustained Release Tablets 30 mg | Note 1 | Rs. 1 4.04 per tablet excluding GST |
Company Claimed Price excluding GST (per tablet) | Rs. 2 0.50 |
Recommended tablet) | price | excluding | GST | ( per tablet) | Rs. 1 4. 04 |
Note 1. Derived retail price as per recommendation of pronabsen commit tee : P(s) = P*.[1+a.{(s-s*)/ s*}]
Where : P(s) =Price ceiling of the strengths
P* = price ceiling for reference strength s* s = strength in terms of API content
s* = reference strength
a= 0.8 for tablet / capsule and 0. 7 for injectibles
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.